Authors:
Kiran Pulidindi, Kavita Yadav
Download free PDF
Microcrystalline Cellulose (MCC) Market Size & Share 2026-2035
Report ID: GMI688
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Microcrystalline Cellulose (MCC) Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Microcrystalline Cellulose (MCC) Market Size
The microcrystalline cellulose (MCC) market was valued at USD 1.28 billion in 2025, is expected to reach USD 1.37 billion in 2026, is projected to grow at a 7% CAGR (2026–2035), and is forecast to reach USD 2.51 billion by 2035.
Microcrystalline Cellulose (MCC) Market Key Takeaways
Market Leader: JRS Pharma GmbH & Co. KG led with over 17% market share in 2025.
Leading Players: Top 5 players in this market include JRS Pharma GmbH & Co. KG, Asahi Kasei Corporation, IFF/DuPont, Roquette Frères, DFE Pharma GmbH & Co. KG, which collectively held a market share of 62% in 2025.
The microcrystalline cellulose (MCC) market is evolving from a broadly specified functional cellulose category into a more differentiated excipient market shaped by pharmaceutical qualification requirements, formulation performance, and feedstock security. Demand is anchored in MCC's ability to combine binding, compressibility, disintegration, moisture-management, and inertness characteristics across solid oral dosage, food, nutraceutical, personal care, and industrial formulations.
GMI Analyst View
Based on our discussions with leading producers across the global MCC supply chain, we view production of approximately 680,000 metric tons in 2025 as evidence that MCC is deeply embedded across multiple downstream industries, while also highlighting the need for further capacity investment as pharmaceutical-grade and differentiated functional applications expand.
Microcrystalline Cellulose (MCC) Market Trends, Growth Drivers & GMI Forecast Outlook
Pharmaceutical manufacturing investment and clean-label food reformulation provide the principal demand base for MCC, while fiber-cost exposure and formulation alternatives shape the pace at which value migrates toward higher-performance grades. Growth depends on suppliers maintaining compendial quality, reliable sourcing, and technical support as end-use requirements become more specialized.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
In pharmaceutical manufacturing, MCC is difficult to displace where a formulation has already been validated around its compression, flow, and disintegration behavior. New tablet and capsule capacity therefore creates recurring qualification demand rather than a one-time equipment-linked purchase. Suppliers able to provide consistent documentation, pharmacopoeial compliance, and formulation support are positioned to capture the highest-value portion of this expansion.
Trade activity also indicates that downstream customers continue to source MCC across borders when grade availability, supply reliability, or technical specifications require it. This favors producers with export-ready quality systems and responsive distribution networks, particularly as formulation plants in emerging manufacturing locations scale output for both domestic use and regulated export markets.
In food and nutraceutical applications, MCC's regulatory familiarity reduces the formulation burden associated with replacing synthetic texture modifiers or introducing novel functional ingredients. Its plant-derived positioning supports reformulation in low-calorie, plant-based, texturized, and dietary-supplement products where moisture control, bulking, suspension, or texture must be achieved without compromising label positioning.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Pulp markets affect MCC suppliers unevenly because exposure depends on the extent of backward integration, procurement scale, and the fiber specifications required by a given grade portfolio. Merchant-pulp-dependent producers face less visibility on margin recovery and may defer investments in purification, particle engineering, or new quality systems when input prices move sharply.
The constraint is more acute in performance-critical pharmaceutical applications, where fiber consistency is inseparable from product quality. Suppliers cannot readily substitute feedstocks without managing implications for alpha-cellulose content, compressibility, and batch reproducibility. This raises the strategic value of diversified fiber access, supplier agreements, and process capability.
Alternative excipient systems are most relevant in demanding formulations rather than as a universal replacement for MCC. Co-processed materials can offer advantages in moisture-sensitive, high-active-load, or flow-challenged tablets, but formulation changes require qualification work. MCC producers can limit displacement by extending portfolios into engineered particle sizes, silicified grades, and co-processed solutions that preserve the material's established regulatory and processing familiarity.
GMI Analyst View
We see the central forecast issue as margin resilience rather than end-market acceptance. Demand from pharmaceutical and food formulators remains durable, but suppliers that control feedstock exposure and offer application-specific grades should be better positioned to retain specification relevance as conventional MCC competes with more engineered excipient systems.
Microcrystalline Cellulose (MCC) Market Segment Analysis
By End Use
The pharmaceutical segment of the microcrystalline cellulose (MCC) market was valued at USD 704 million in 2025 and is projected to reach USD 1.42 billion by 2035. Its position reflects MCC's role as a binder, disintegrant, and direct-compression diluent in solid oral dosage manufacturing, where validated product files and compendial expectations create meaningful switching barriers for formulators.
Food and beverage applications accounted for 24.0% of the market in 2025 and are forecast to reach USD 576 million by 2035. Demand is supported by MCC's use as a fat replacer, texture modifier, suspension stabilizer, and bulking ingredient in processed food, nutritional beverages, bakery products, and plant-based formulations seeking clean-label functionality.
Cosmetics and personal care applications represented 11.0% of the market in 2025 and are expected to contribute USD 282 million by 2035. In this segment, MCC is used for absorbency, rheology modification, sensory adjustment, and suspension control, particularly where formulators seek functional performance without heavier reliance on synthetic polymer systems.
Other end uses were valued at USD 128 million in 2025 and are expected to represent 9.1% of the market by 2035. Nutraceutical tablets, animal-health products, paper coatings, polymer processing, and specialty industrial applications broaden MCC's demand base and provide outlets for grades tailored to different performance and compliance requirements.
By Grade
Pharmaceutical-grade MCC was valued at USD 742 million — equivalent to a 58.0% share — in 2025 and is projected to reach USD 1.53 billion by 2035. Its leadership stems from the grade's fit with regulated tablet and capsule manufacturing, where pharmacopoeial conformity, traceability, and reproducible performance are integral to supplier qualification.
Food-grade MCC accounted for 27.0% of the market in 2025 and is expected to reach USD 650 million by 2035. Although its compliance requirements differ from pharmaceutical applications, particle-size consistency, moisture control, and microbiological quality remain important procurement considerations for food producers supplying regulated consumer markets.
Industrial-grade MCC represented 15.0% of the market in 2025 and is projected to grow at a 5.6% CAGR (2026–2035). Its application base includes paper coating, polymer processing, specialty chemicals, and construction-material modification, where the material's structural and binding properties can support bio-based material development with broader feedstock flexibility.
By Source
Wood-based MCC represented 442,000 metric tons — a 65.0% share — in 2025 and is expected to reach 720,000 metric tons by 2035. Established pulp infrastructure, predictable fiber characteristics, and longstanding process knowledge support its leadership, although dependence on conventional wood-pulp supply chains also heightens attention to procurement resilience.
Cotton-based MCC represented 136,000 metric tons — representing 20.0% — in 2025 and is forecast to grow at a 5.4% CAGR (2026–2035). Cotton linter can offer high alpha-cellulose content that is attractive in pharmaceutical uses, but availability is shaped by competing uses in specialty paper, filtration, and nitrocellulose value chains.
Bamboo-sourced MCC accounted for 15.0% of the market in 2025 and is projected to reach 209,000 metric tons by 2035. Its strategic appeal lies in feedstock diversification, shorter cultivation cycles, and alignment with sustainability-led sourcing requirements, although commercial scale-up will depend on consistent purification, processing, and quality-control performance.
GMI Analyst View
We view pharmaceutical end use and pharmaceutical-grade MCC as the market's technical center of gravity because their qualification requirements influence investment in quality systems, analytical support, and process control. At the same time, alternative cellulose sources could become more strategically relevant as producers seek feedstock options that reduce conventional pulp exposure without compromising grade consistency.
Microcrystalline Cellulose (MCC) Market Regional Analysis
North America Microcrystalline Cellulose (MCC) Market Analysis
The microcrystalline cellulose (MCC) market in North America was valued at USD 384 million — a 30.0% share — in 2025 and is projected to reach USD 704 million by 2035. The region's established pharmaceutical manufacturing, nutraceutical demand, and high quality-assurance expectations support procurement of documented, pharmacopoeia-compliant MCC grades.
United States
The United States was valued at USD 346 million — a 27.0% share — in 2025 and is expected to reach USD 634 million by 2035. Pharmaceutical contract manufacturing, dietary supplements, and complex solid-dose formulations create demand for suppliers that can demonstrate reliable batch consistency and meet rigorous documentation requirements.
Europe Microcrystalline Cellulose (MCC) Market Analysis
Europe accounted for 22.0% of the market in 2025 and is forecast to reach USD 495 million — representing 19.7% — by 2035. Its mature pharmaceutical, nutraceutical, and clean-label food industries support steady demand for qualified MCC, while stringent quality and traceability requirements make supplier changes more deliberate than in less regulated end markets.
Germany
Germany represented 4.0% of the market in 2025 and is expected to reach USD 89 million by 2035. Demand is supported by the country's pharmaceutical manufacturing, fine-chemical production, and focus on complex, high-value dosage forms that require well-characterized excipient performance.
United Kingdom
The United Kingdom accounted for 3.5% of the market in 2025 and is projected to reach USD 74 million by 2035. Contract formulation, generic-drug production, and multiple regulatory documentation requirements reinforce procurement from established, pharmacopoeia-compliant supply chains.
France
France was valued at USD 39 million in 2025 and is expected to reach USD 69 million by 2035. Pharmaceutical and nutraceutical manufacturing, together with demand from processed-food applications, support a market where technical formulation support and regional supply relationships remain important competitive considerations.
Asia Pacific Microcrystalline Cellulose (MCC) Market Analysis
Asia Pacific was valued at USD 486 million — a 38.0% share — in 2025 and is projected to reach USD 1.05 billion by 2035. The region combines expanding pharmaceutical production, rising domestic drug consumption, increasing functional-food output, and a substantial base of MCC manufacturers, creating both the largest demand pool and an increasingly competitive supply environment.
China
China was valued at USD 179 million — a 14.0% share — in 2025 and is forecast to reach USD 411 million by 2035. Its dual role as a major manufacturing base and consuming market strengthens domestic demand for MCC across pharmaceutical and food applications, while rising quality expectations support the shift toward more certified grades.
India
India was valued at USD 102 million — an 8.0% share — in 2025 and is projected to grow at a 10.5% CAGR (2026–2035). Pharmaceutical manufacturing investment, expanding domestic drug demand, and export-oriented formulation capacity reinforce the need for reliable pharmacopoeia-grade MCC and support local suppliers seeking to broaden grade capability.
Japan
Japan is expected to reach USD 165 million — representing a 6.6% share — by 2035 and is projected to grow at a 4.5% CAGR (2026–2035). The market is characterized by mature pharmaceutical and functional-food sectors where performance consistency, technical documentation, and differentiated direct-compression grades are central to supplier selection.
South Korea
South Korea represented 3.5% of the market in 2025 and is expected to reach USD 86 million by 2035. The country's finished-dosage and pharmaceutical-ingredient manufacturing base supports demand for qualified MCC that meets domestic and export-market quality expectations.
Latin America Microcrystalline Cellulose (MCC) Market Analysis
Latin America is expected to reach USD 130 million by 2035 and is projected to grow at a 7.5% CAGR (2026–2035). Pharmaceutical manufacturing modernization, increasing dietary-supplement consumption, and the expansion of regional food processing support a gradual shift toward higher-specification excipient procurement.
Brazil
Brazil accounted for 3.5% of the market in 2025 and is expected to reach USD 88 million by 2035. Generic-drug production, branded formulations, and nutraceutical consumption anchor demand, while progressively stronger manufacturing oversight favors established suppliers with robust quality documentation.
Middle East & Africa Microcrystalline Cellulose (MCC) Market Analysis
The Middle East & Africa market was valued at USD 64 million — a 5.0% share — in 2025 and is forecast to grow at a 7.7% CAGR (2026–2035). Growing pharmaceutical localization efforts create incremental demand for imported, quality-certified MCC because local production capacity remains limited relative to downstream formulation requirements.
Saudi Arabia
Saudi Arabia was valued at USD 10 million — a 0.8% share — in 2025 and is expected to reach USD 20 million by 2035. Healthcare localization and new domestic formulation capacity support demand for compendial-grade excipients as manufacturers operate under increasingly formalized quality requirements.
UAE
The UAE accounted for 0.6% of the market in 2025 and is expected to reach USD 18 million by 2035. Pharmaceutical and nutraceutical operations in regulated industrial zones rely on efficient import channels and established international suppliers to secure the documentation and grade consistency needed for regional and export-oriented production.
GMI Analyst View
We see a divided regional demand pattern. Mature markets place greater value on formulation complexity, documentation, and premium applications, while high-growth markets are adding manufacturing capacity and broadening domestic consumption. The key strategic question is whether emerging production hubs can pair volume expansion with quality systems capable of serving regulated export markets.
Microcrystalline Cellulose (MCC) Market Share & Competitive Landscape
The microcrystalline cellulose (MCC) market share structure is moderately concentrated, with the five largest producers holding approximately 62% of the market. Competition is shaped less by standard-grade capacity alone than by pharmaceutical qualification depth, particle-engineering capability, feedstock access, formulation support, and the ability to provide reliable supply across multiple regulatory jurisdictions.
JRS Pharma held approximately 17% of the market in 2025. Its competitive position is supported by a broad portfolio of pharmacopoeia-compliant MCC grades, allowing customers to source differing particle-size, moisture, and compression profiles within a single qualified supplier relationship.
Asahi Kasei held approximately 13% of the market in 2025 through its Ceolus™ portfolio. The company's positioning rests on differentiated pharmaceutical-grade performance in direct-compression applications, where particle engineering and reproducible tablet characteristics can justify premium supplier selection.
Roquette strengthened its excipient position when it completed the acquisition of IFF Pharma Solutions on May 1, 2025 [4]Roquette Frères. "Roquette Completes Acquisition of IFF Pharma Solutions." roquette.com. The acquired business held an estimated 12% pre-acquisition share, expanding Roquette's MCC presence and deepening its ability to engage pharmaceutical formulators through a broader functional-excipient offering.
DFE Pharma remains differentiated as a focused pharmaceutical-excipient supplier, with its Pharmacel® MCC range addressing direct compression, wet granulation, and extrusion-spheronization applications. Its dedicated technical documentation and formulation support are particularly relevant where supplier qualification is based on performance evidence rather than price alone.
Asian producers, including Mingtai Chemical, Sigachi Industries, Anhui Sunhere Pharmaceutical Excipients, Nitika Pharmaceutical Specialities, Ankit Pulps & Boards, Chemfield Cellulose, Shandong Head, Arakawa Chemical Industries, Accent Microcell, and Amishi Drugs & Chemicals, sustain intense competition in standard and progressively higher-grade MCC. Their ability to increase quality assurance, secure feedstocks, and build export-ready compliance systems will influence how market share shifts between established multinational suppliers and regional specialists.
Recent Industry Developments
Sigachi Industries began an MCC expansion at its Dahej, Gujarat facility in August 2025, targeting additional production capacity for the Indian market [5]Construction World India. "Sigachi Begins Rs 1.5 Billion MCC Expansion in Gujarat." constructionworld.in. The development signals supplier confidence in domestic pharmaceutical and nutraceutical demand, while underscoring the importance of aligning capacity additions with pharmaceutical-grade quality requirements.
Asahi Kasei announced patent infringement proceedings involving its Ceolus™ technology in November 2025 [6]Asahi Kasei Corporation. "Notice of Filing of Patent Infringement Lawsuit." asahi-kasei.com. The action reflects intensifying competition around pharmaceutical-grade MCC performance differentiation as producers seek to commercialize technically advanced grades in regulated markets.
Oji Holdings made a strategic investment in Nordic Bioproducts Group in January 2026, focused on MCC production technology [7]Nordic Bioproducts Group. "Japan's Oji Holdings Makes Strategic Investment in Finnish Biomaterials Deep Tech Company Nordic Bioproducts Group." nordicbioproducts.fi. The transaction illustrates increasing interest in alternative cellulose-processing routes and suggests that feedstock diversification and higher-purity production technologies are becoming more prominent strategic themes.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →